MERUS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.02 USD | +4.70% |
|
+15.19% | +70.98% |
| 04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| 03-28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MERUS N.V. | Bio Therapeutic Drugs | +4.70% | +15.19% | +70.98% | +145.15% | +204.53% | 2.64B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- MRUS Stock
- Charts Merus N.V.
- Comparison Chart
